Literature DB >> 8642307

Hybrid antibody mediated veto of cytotoxic T lymphocyte responses.

Y Qi1, R Berg, M A Singleton, J E Debrick, U D Staerz.   

Abstract

Strategies are being sought that allow the induction of specific tolerance to allogeneic transplants without affecting other immune functions. The so-called veto effect has been described as one such technology where CD8+ cells suppress responses of class I MHC-restricted T-lymphocyte precursors to antigens expressed by those CD8+ veto cells. Yet, veto inhibition will not be able to provide complete tolerance to allogeneic grafts since it only operates on cell populations that express CD8. Other types of cells prevalent in most organs express different tissue-specific antigens that are recognized by alloreactive T-cells. Therefore, complete tolerance to an allogeneic transplant can only be achieved if all cellular components within the graft acquire the immune-inhibitory function. Here, we studied whether the veto effect could be exploited for this purpose nevertheless. We produced a hybrid antibody (HAb) combining a mAb specific for a class I MHC molecule with a soluble CD8 molecule. We found that this HAb specifically and effectively transferred veto inhibition to different stimulator cell populations. Thus, we have developed a strategy that promises to selectively and completely tolerize graft-specific CTLs without affecting normal immune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642307      PMCID: PMC2192550          DOI: 10.1084/jem.183.5.1973

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

Review 1.  Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies.

Authors:  S P Cobbold; S Qin; L Y Leong; G Martin; H Waldmann
Journal:  Immunol Rev       Date:  1992-10       Impact factor: 12.988

2.  Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC.

Authors:  S R Sambhara; R G Miller
Journal:  Science       Date:  1991-06-07       Impact factor: 47.728

3.  Regulation of allogeneic responses by expression of CD8 alpha chain on stimulator cells.

Authors:  J E Hambor; M C Weber; M L Tykocinski; D R Kaplan
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

Review 4.  Veto function in vitro and in vivo.

Authors:  H G Rammensee
Journal:  Int Rev Immunol       Date:  1989-05       Impact factor: 5.311

5.  Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules.

Authors:  M H Newberg; J P Ridge; D R Vining; R D Salter; V H Engelhard
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

6.  Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 A resolution.

Authors:  D J Leahy; R Axel; W A Hendrickson
Journal:  Cell       Date:  1992-03-20       Impact factor: 41.582

7.  Kidney allograft tolerance in primates without chronic immunosuppression--the role of veto cells.

Authors:  J M Thomas; F M Carver; P R Cunningham; L C Olson; F T Thomas
Journal:  Transplantation       Date:  1991-01       Impact factor: 4.939

8.  On the nature of peptides involved in T cell alloreactivity.

Authors:  O Rötzschke; K Falk; S Faath; H G Rammensee
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

9.  Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.

Authors:  J Fangmann; R Dalchau; J W Fabre
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes.

Authors:  K Hiruma; H Nakamura; P A Henkart; R E Gress
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

2.  Inhibition of cytotoxic alloreactivity by human allogeneic mononuclear cells: evidence for veto function of CD2+ cells.

Authors:  G Raddatz; A Deiwick; T Sato; H J Schlitt
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 3.  New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Authors:  Mark L Tykocinski; Aoshuang Chen; Jui-Han Huang; Matthew C Weber; Guoxing Zheng
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.